Videos

The panel discusses how patients with ROS1-positive advanced NSCLC arrive in clinic through in-system diagnosis, second opinions, or new patient referrals and the detective work required to ensure complete molecular testing is available before treatment decisions.

ROS1 gene fusions occur in approximately 1% to 2% of advanced NSCLC cases, a small but clinically meaningful subset predominantly found in younger patients, women, light or never smokers, and those with non-squamous histology, most commonly adenocarcinoma.

ANK-101, an IL-12 anchored immunotherapy, is being studied with checkpoint blockade in patients with non–small cell lung cancer in a phase 1b trial.

With 4 ROS1-directed TKIs now in the mix, community oncologists need a clear framework for sequencing and CNS considerations in this rare NSCLC subset.

ASCO 2026 highlights: KRAS signals, ADC‑immunotherapy momentum, and new TNBC/HER2 breakthroughs shaping next breast cancer trials.

Raj Singh, MD, discusses treatment gaps, emerging therapies, and the critical role of multidisciplinary care in managing brain tumors.

VIKTORIA-1 shows gedatolisib regimens double PFS and cut hyperglycemia vs alpelisib in PIK3CA-mutant HR+/HER2– breast cancer.

Living in food deserts links to aggressive ctDNA mutations and shorter metastatic breast cancer survival, with the starkest survival gaps seen in Black patients.

James W. Smithy, MD, MHS, discusses the key findings from a phase 2 trial of IO102-IO103 plus nivolumab/relatlimab in advanced melanoma.

Phase 2 study presented at ASCO 2026 shows fedratinib eases symptoms and shrinks spleens in rare MDS/MPN variants, offering a needed evidence-based option.

Allostatic load links chronic stress and social factors to early-onset cancer risk, offering a measurable path to improve risk models and prevention strategies.

Saad Z. Usmani, MD, MBA, shares guidance on improving tolerability of belantamab mafodotin based on clinical experience and findings from in the DREAMM-9 trial.

Saad Z. Usmani, MD, MBA, discusses the significance of the final analysis of the phase 3 CEPHEUS trial in newly diagnosed multiple myeloma.

ASCO 2026 data link chronic-stress allostatic load to higher early-onset cancer risk, suggesting new tools for screening beyond genetics.

Dr Tolaney discusses ASCENT-04 data, showing sacituzumab govitecan plus pembrolizumab improves PFS in 1L mTNBC across all Trop-2, tBRCA, and HER2 subgroups.

Michael C. Heinrich, MD, discusses the eventual goal of using velzatinib as an early-line treatment for gastrointestinal stromal tumors.

Mabel Mardones, MD, discusses findings from the phase 3 perservERA trial presented at ASCO 2026.

ASCO 2026 insights on 177Lu-PSMA-617 in mHSPC: safety, marrow and kidney monitoring, and what long-term MDS/AML risks may reveal.

Michael C. Heinrich, MD, discusses promising KIT mutation analyses from the phase 1b StrateGIST study in gastrointestinal stromal tumors.

Long-term INDIGO data show vorasidenib extends progression-free survival, delays next treatment, and cuts seizures in post-surgery IDH-mutant glioma.

ASCO 2026: PSMAddition shows 177Lu-PSMA-617 boosts rPFS across mHSPC subgroups, with steady safety and insights on PSMA PET selection.

Andrew L. Pecora, MD, discusses the significance of the long-term findings from the KEYNOTE-942 trial of intismeran autogene and how it enhances the immune response.

Dr Pant highlights phase 3 data showing oral daraxonrasib nearly doubles overall survival vs chemotherapy in metastatic pancreatic cancer.

Dr McDonald shares promising data linking GLP-1 use to lower breast cancer risk, highlighting the need for clinical trials to prove prevention.

Andrew J. Wagner, MD, PhD reviews phase 3 PEAK data on bezuclastinib plus sunitinib in advanced GIST at ASCO 2026.

Roberto Mina, MD, discusses takeaways from the MajesTEC-9 trial results at ASCO.

Daniel Olson, MD, discusses the results of a phase 1 trial of brenetasfusp, a PRAME ImmTAC therapy in advanced melanoma.

SENOMAC at ASCO 2026 shows skipping completion ALND in select breast cancer keeps survival high and cuts lymphedema, boosting quality of life.

APP-led benign hematology consults boost access in community oncology—cut wait times, expand capacity, and show how teams scale safely.

Discover the final 7.8-year survival data from KEYNOTE-522 and see how adding pembrolizumab to chemotherapy drastically cuts recurrence for early TNBC.